TORONTO, Nov. 8, 2017 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) makes the following announcement concerning its holding of 6,341,500 common shares in Biohaven Pharmaceutical Holding Company Limited (BHVN:NYSE):
This statement is provided for shareholders who are United States
Portage is a non-U.S. entity continued as BVI Business Company since July 5, 2013 under the BVI Business Companies Act, 2004 in the British Virgin Islands. You should be aware that, based on the nature and amount of Portage's projected income and assets for the fiscal year ending March 31, 2018, Portage may be treated as a passive foreign investment company ("PFIC") as defined in Section 1297(a) of the IRC, for the fiscal year ending March 31, 2018.
The Portage Board of Directors has agreed to make an Annual Information Statement available to shareholders pursuant to the requirements of Treasury Regulation Section 1.1295-1(g) (1). The PFIC Annual Information Statement will contain information to enable Portage Shareholders to elect to treat their investment in Portage as a qualified electing fund ("QEF"), should they so choose based on the advice of their tax advisors in light of their personal tax circumstances.
THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST SHAREHOLDERS IN MAKING THEIR OWN DECISION REGARDING FILING OF A QEF ELECTION AND DOES NOT CONSTITUTE TAX ADVICE. THE U.S. TAX LAWS REGARDING PFICS ARE EXTREMELY COMPLEX AND SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THEIR RESPECTIVE INVESTMENT IN, AND OWNERSHIP OF SHARES OF PORTAGE UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.
Further information on the PFIC rules and the QEF election is available from the Internal Revenue Service, including the following website pages:
For Canadian and UK shareholders :
Certain notable facts regarding our listing on Canadian Securities Exchange (refer to http://thecse.com/support/investors)
Portage assumes no obligation for, and expressly disclaims any duty to update, the information in this News Release.
SOURCE Portage Biotech Inc.
Subscribe to our Free Newsletters!
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...View All